Skip to main content
Signal8

PaxMedica, Inc. Common Stock (PXMD)

PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.

Sector: Biotechnology

Industry: Biotechnology

PaxMedica, Inc. Common Stock logo

PaxMedica, Inc. Common Stock

OTC:PXMDHealthcare
$0.0005
CLOSED
Mkt Cap$63K
EV-
Float10.69M
O/S126.26M
VOL759 sh
$ Vol$0
RVOL0.14×
Inst Own-
SI<0.1%
Net Cash/Sh-
EarningsDec 2 · in 2w
Dilution
PaxMedica, Inc. Common Stock logoOTC:PXMDClosed$0.0005
Financials Summary
Revenue$0
Net Income-$18.29M
Total Assets$5.68M
Free Cash Flow-$10.77M
Debt & Equity
Equity 100%
Preferred 0%
Total Debt$0
Total Equity$3.39M
Preferred Stock$5
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
  1. 1:17Reverse split
    Oct 31, 202317 shares → 1
Balance Sheet Details
Assets$5.68M
Liabilities$2.3M
Accounts Receivable$0
Accounts Payable$812K
Inventory$0
PP&E (Net)$0
Goodwill$0
Intangible Assets$0
Income Statement
PeriodFY 2023FY 2022FY 2021FY 2020FY 2019
CurrencyUSDUSDUSDUSDUSD
Period Ending2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$0$0$0$0$0
YoY Growth-----
Cost of Revenue$0$0$0$0$0
Gross Profit$0$0$0$0$0
Gross Margin-----
Research and Development$3.92M$1.79M$2.23M$937K$484K
Selling, General, and Administrative$12.23M$8.82M$4.97M$4.63M$114K
Other$0$0$0$224$0
Total Operating Expenses$16.14M$10.6M$7.2M$5.57M$599K
Operating Income (EBIT)-$16.14M-$10.6M-$7.2M-$5.57M-$599K
Operating Margin-----
Interest Expense$9K$5K$2.81M$609K$0
Interest Income$0$0$0$0$0
Other Income (Expense)-$2.14M-$4.2M-$3.03M-$2.26M$0
Income Before Tax (EBT)-$18.29M-$14.8M-$10.23M-$7.83M-$599K
Income Tax Expense$0$4.19M$2.81M$663K$0
Net Income-$18.29M-$14.8M-$13.04M-$8.49M-$599K
Net Income Margin-----
Supplementary Data
EPS-11.00-28.73-18.81-13.42-0.06
Diluted EPS-11.00-28.73-18.81-13.42-0.06
Weighted Average OS1.66M514,216692,910589,198589,198
EBITDA-$16.14M-$16.51M-$7.2M-$5.62M-$599K
EBITDA Margin-----
Balance Sheet
PeriodFY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
CurrencyUSDUSDUSDUSDUSDUSD
Period Ending2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Assets
Current Assets
Cash and Cash Equivalents$4.71M$1.9M$444K$1.12M$25K$9K
Short-Term Investments$0$0$0$0$0$0
Cash and Short-Term Investments$4.71M$1.9M$444K$1.12M$25K$9K
Accounts Receivable$0$0$0$0$0$0
Inventory$0$0$0$0$0$0
Other Current Assets$970K$302K$0$0$0$0
Total Current Assets$5.68M$2.2M$444K$1.12M$25K$9K
Long-Term Assets
Property, Plant & Equipment Net$0$0$0$0$0$0
Goodwill$0$0$0$0$0$0
Intangible Assets$0$0$0$0$0$0
Long-Term Investments$0$0$0$0$0$0
Deferred Tax Assets$0$0$0$0$0$0
Other Long-Term Assets$0$0$205K$0$0$0
Total Long-Term Assets$0$0$205K$0$0$0
Other Assets$0$0$0$0$0$0
Total Assets$5.68M$2.2M$649K$1.12M$25K$9K
Liabilities
Current Liabilities
Accounts Payable$812K$722K$736K$346K$41K$0
Short-Term Debt$0$174K$0$612K$0$0
Current Income Tax Payable$0$0$0$0$0$0
Current Unearned Revenue$0$0$0$634K$0$0
Other Current Liabilities$788K$661K$9.34M$3.42M$0$0
Total Current Liabilities$1.8M$2.1M$10.76M$5.75M$123K$7K
Long-Term Liabilities
Long-Term Debt$0$0$0$0$0$0
Long-Term Unearned Revenue$500K$0$0$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0$0$0
Other Long-Term Liabilities$0$0$0$0$0$0
Total Long-Term Liabilities$500K$915K$737K$1.06M$0$2K
Other Liabilities$0-$915K-$737K-$1.06M$0-$2K
Total Liabilities$2.3M$2.1M$10.76M$5.75M$123K$7K
Stockholders' Equity
Preferred Stock$5$5$270$270$766K$232K
Common Stock$740$71$691$578$0$0
Retained Earnings-$52.03M-$33.74M-$18.94M-$8.71M-$864K-$229K
Comprehensive Income & Other-$740$0$0$0$0$0
Other Stockholders' Equity$55.41M$33.85M$8.83M$4.08M$766K$232K
Total Equity$3.39M$109K-$10.11M-$4.63M-$98K$3K
Minority Interest$0$0$0$0$0$0
Total Liabilities and Equity$5.68M$2.2M$649K$1.12M$25K$9K
Supplementary Data
Total Debt$0$174K$0$612K$0$0
Net Debt-$4.71M-$1.73M-$444K-$512K-$25K-$9K
Cash Flow Statement
PeriodFY 2023FY 2022FY 2021FY 2020FY 2019
CurrencyUSDUSDUSDUSDUSD
Period Ending2023-12-312022-12-312021-12-312020-12-312019-12-31
Operating Activities
Net Income-$18.29M-$14.8M-$10.23M-$7.83M-$599K
Depreciation & Amortization$0$0$0$0$0
Deferred Income Tax$0$0$0$0$0
Stock-Based Compensation$5.2M$4.42M$1.34M$2.26M$0
Changes in Working Capital:
  Accounts Receivable$0$0$0$0$0
  Inventory$0$0$0$0$0
  Accounts Payable$456K$114K$250K$393K$54K
  Other Working Capital-$122K-$64K$102K$569K$63K
Total Working Capital Change$334K$50K$352K$962K$117K
Other Non-Cash Items$1.98M$4.26M$3.03M$2.25M$63K
Net Cash from Operating-$10.77M-$6.07M-$5.51M-$2.35M-$419K
Investing Activities
Capital Expenditures$0$0$0$0$0
Acquisitions$0$0$0$0$0
Purchases of Investments$0$0$0$0$0
Sales of Investments$0$0$0$0$0
Other Investing Activities$0$0$0$0$0
Net Cash from Investing$0$0$0$0$0
Financing Activities
Debt Repaid----$2.93M-
Common Stock Issuance$11.95M$6.02M$5M$0$0
Common Stock Repurchases-$196K-$35K$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing Activities-$626K-$35K-$167K$520K$435K
Net Cash from Financing$13.58M$7.53M$4.83M$3.45M$435K
Forex Effect$0$0$0$0$0
Net Change in Cash$2.81M$1.46M-$680K$1.1M$16K
Supplementary Data
Operating Cash Flow-$10.77M-$6.07M-$5.51M-$2.35M-$419K
Capital Expenditure$0$0$0$0$0
Free Cash Flow-$10.77M-$6.07M-$5.51M-$2.35M-$419K
Cash at Beginning$1.9M$444K$1.12M$25K$9K
Cash at End$4.71M$1.9M$444K$1.12M$25K